Organon & Co. (OGN)
NYSE: OGN · Real-Time Price · USD
8.60
-0.54 (-5.91%)
Apr 23, 2026, 2:33 PM EDT - Market open
Organon & Co. Revenue
In the year 2025, Organon & Co. had annual revenue of $6.22B, down -2.92%. Organon & Co. had revenue of $1.51B in the quarter ending December 31, 2025, a decrease of -5.34%.
Revenue (ttm)
$6.22B
Revenue Growth
-2.92%
P/S Ratio
0.37
Revenue / Employee
$621,600
Employees
10,000
Market Cap
2.24B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6.22B | -187.00M | -2.92% |
| Dec 31, 2024 | 6.40B | 140.00M | 2.24% |
| Dec 31, 2023 | 6.26B | 89.00M | 1.44% |
| Dec 31, 2022 | 6.17B | -130.00M | -2.06% |
| Dec 31, 2021 | 6.30B | -228.00M | -3.49% |
| Dec 31, 2020 | 6.53B | -1.25B | -16.01% |
| Dec 31, 2019 | 7.78B | -2.00B | -20.46% |
| Dec 31, 2018 | 9.78B | -723.00M | -6.89% |
| Dec 31, 2017 | 10.50B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Pfizer | 62.58B |
| Sanofi | 54.85B |
| Bristol-Myers Squibb Company | 48.19B |
| GSK plc | 43.97B |
| Gilead Sciences | 29.44B |
| Biogen | 9.89B |
| Grifols | 8.83B |
| Amarin Corporation | 213.65M |
OGN News
- 7 days ago - Organon To Report First Quarter 2026 Results and Host Conference Call on May 7, 2026 - Business Wire
- 8 days ago - Organon's VTAMA® (tapinarof) cream, 1%, Granted Strong Recommendation in the 2026 American Academy of Dermatology Guidelines for Pediatric Atopic Dermatitis - Business Wire
- 13 days ago - Sun Pharma Nears Final Offer For Organon In Largest Overseas Bet - Benzinga
- 13 days ago - This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring. - Barrons
- 13 days ago - This Women's Healthcare Stock Is Up 15% on Reports of a Takeover In the Works - Investopedia
- 13 days ago - These Stocks Are Today's Movers: Nvidia, Intel, Lumentum, Coherent, Organon, and More. - Barrons
- 27 days ago - Organon Debuts New Analysis of VTAMA® (tapinarof) cream, 1%, Phase 3 Pooled Data Demonstrating Early and Consistent Skin Clearance and Itch Improvement in Atopic Dermatitis Patients Down to 2 Years of Age - Business Wire
- 4 weeks ago - US FDA flags seizure risk with certain Parkinson's drugs, seeks label warnings - Reuters